Compare ICHR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICHR | PVLA |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2016 | N/A |
| Metric | ICHR | PVLA |
|---|---|---|
| Price | $96.71 | $139.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $49.50 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 1.3M | 328.6K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $947,652,000.00 | N/A |
| Revenue This Year | $20.51 | N/A |
| Revenue Next Year | $17.08 | $104,350.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $13.15 | $24.07 |
| 52 Week High | $113.58 | $161.38 |
| Indicator | ICHR | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 58.32 |
| Support Level | $60.40 | $106.07 |
| Resistance Level | N/A | $151.18 |
| Average True Range (ATR) | 8.36 | 9.55 |
| MACD | 0.41 | 2.75 |
| Stochastic Oscillator | 38.66 | 58.26 |
Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.